News

Performance metrics of NIS4, the ELF test, and FibroMeter VCTE met prespecified criteria for qualification for regulatory approval in stage 1 of the NIMBLE project's circulating biomarker workstream.

Results from the 2-year retrospective cohort study showed patients with DME and extremely high or low eGFR had a greater decline in eGFR.

Jeffrey Sparks, MD, MMSc, explains how to tailor rheumatoid arthritis treatment for an individual patient’s needs and when to consider switching or intensifying treatment.

Yvonne C. Lee, MD, MMSc, explains the pain mechanisms in rheumatic disease and the promising advancements in pain research.

In this segment of her Q&A interview, Dr. Cotton discussed several major topics covered in her upcoming SHSA Conference presentation on pediatric HS.

A nationwide cohort study shows individuals with a history of infection are at a nearly 50% greater likelihood of dementia development in older age.

In this episode, hosts sit down for a discussion around a recent NEJM report assessing the effects of semaglutide use in people with type 1 diabetes, including the implications of the findings and their real-world experiences with GLP-1 use in people with type 1 diabetes.

Susan Goodman, MD, discusses pre and perioperative management of rheumatic disease.

This new Q&A interview with Dr. Cotton featured a discussion on the issues facing pediatric HS patients and other topics covered in her upcoming SHSA Conference presentation.

Patients with CDI treated with oral metronidazole experienced significantly more first-line drug changes compared to those on fidaxomicin, although there were no significant differences observed in the global or clinical cure rate between the two treatments.

On September 7, 2023, Alnylam Pharmaceuticals announced positive topline data from the phase 2 KARDIA-1 trial of zilbesiran in the treatment of hypertension.

Analyses suggest users of calcium channel blockers had 39% higher odds of glaucoma compared with non-users, after controlling for confounders.

This new data had both a consistent long-term safety and tolerability profile with the previous short-term results for the skin disease, and there were no new safety signals recorded.

A program from the American Oncology Network shows promise to introducing cost-efficient biosimilar substitution opportunities to prescribers and payors.

Investigators observed higher rates of clinical and endoscopic remission among patients with UC treated with FMT compared to those on control treatments, further noting comparable rates of adverse reactions between the groups.

A meta-analysis of 7 prospective or retrospective cohort studies conducted in Asia and Europe suggests a diagnosis of gout or hyperuricemia was linked to a lower risk of Alzheimer disease.

An analysis from Taiwan suggest immunogenicity differences are limited between biosimilars approved by the FDA and their reference biologic products.

A treat-and-extend faricimab regimen may improve functional and anatomical outcomes at 1 year in patients with DME recalcitrant to aflibercept treatment.

A case series of 10 patients with newly diagnosed type 1 diabetes provides insight into the beneficial effects of off-label semaglutide use on insulin use, HbA1c, and fasting C-peptide levels among this patient population.

Investigators noted the prevalence of metabolic syndrome was highest among participants with obesity, linking increased BMI to a greater risk of metabolic syndrome and NAFLD severity.

The University of Miami study previews the upcoming phase 3 trial and what the investigative seladelpar may provide patients with primary biliary cholangitis.

The study evaluated 10-year outcomes of anti-VEGF therapy using a PRN treatment regimen for eyes with neovascular AMD in real-world clinical practice.

Vedolizumab, anti-TNF, and 5-ASA treatments were not linked to an increased risk of CDI, but investigators noted other baseline variables were significantly associated with CDI risk in patients with IBD.

The phase 3 seladelpar investigator discusses the current landscape of care available for patients with PBC.

An analysis of CDC data from 1999 to 2020 offers clinicians a snapshot of overall, and race-specific, trends in obesity-related cardiovascular disease deaths since the turn of the century.

This test provides a useful approach as it can be less intensive for time and resources, less costly, and it can be conducted outside of the specialist allergy setting.

A switch from a biologic treatment to a biosimilar demonstrated comparable effects for both primary and co-primary outcomes in patients with rheumatoid arthritis.

An analysis of more than 4000 adolescents and young adults in the US found those who more recently used tobacco products reported more symptoms than other users.

Given that this new research was an exploratory study with a smaller sample size, the study’s results may not be generalized and future studies should use more patients and institutions.

After stratifying for gender, age, and ethnicity, hyperuricemia remained positively associated with nephrolithiasis.